These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 32583494)

  • 1. Serum levels of inflammatory markers CRP, ESR and albumin in relation to survival for patients with hepatocellular carcinoma.
    Akkiz H; Carr BI; Bag HG; Karaoğullarından Ü; Yalçın K; Ekin N; Özakyol A; Altıntaş E; Balaban HY; Şimşek H; Uyanıkoğlu A; Balkan A; Kuran S; Üsküdar O; Ülger Y; Güney B; Delik A
    Int J Clin Pract; 2021 Feb; 75(2):e13593. PubMed ID: 32583494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum Inflammation Parameters and Survival in Hepatocellular Carcinoma Patients: Importance of Albumin and Gamma-Glutamyltranspeptidase.
    Carr BI; Guerra V
    Oncology; 2023; 101(5):313-320. PubMed ID: 36878197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Portal Vein Thrombosis and Markers of Inflammation in Hepatocellular Carcinoma.
    Carr BI; Guerra V; Donghia R
    J Gastrointest Cancer; 2020 Dec; 51(4):1141-1147. PubMed ID: 32851544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRP is a superior and prognostically significant inflammation biomarker for hepatocellular cancer patients treated by liver transplantation.
    Carr BI; Ince V; Bag HG; Usta S; Ersan V; Isik B; Yilmaz S
    Clin Pract (Lond); 2021; 18(2):1626-1632. PubMed ID: 33972830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in Tumor Indices in Relation to Increased Hepatocellular Carcinoma Size: Evidence for Tumor Evolution as a Function of Growth.
    Carr BI; Guerra V; Donghia R; Yilmaz S
    J Gastrointest Cancer; 2020 Dec; 51(4):1215-1219. PubMed ID: 33006073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Clinical Phenotypes and Related Survival in Patients with Large HCCs.
    Carr BI; Guerra V; Donghia R; Farinati F; Giannini EG; Muratori L; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Sacco R; Celsa C; Campani C; Mega A; Guarino M; Gasbarrini A; Svegliati-Baroni G; Foschi FG; Biasini E; Masotto A; Nardone G; Raimondo G; Azzaroli F; Vidili G; Brunetto MR; Trevisani F
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33546234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor multifocality and serum albumin levels can identify groups of patients with hepatocellular carcinoma and portal vein thrombosis having distinct survival outcomes.
    Carr BI; Guerra V; Donghia R; Yilmaz S
    Ann Med Surg (Lond); 2021 Jun; 66():102458. PubMed ID: 34141428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum albumin levels in relation to tumor parameters in hepatocellular carcinoma patients.
    Carr BI; Guerra V
    Int J Biol Markers; 2017 Oct; 32(4):e391-e396. PubMed ID: 28862714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of gamma-glutamyl transpeptidase in relation to HCC human biology and prognosis.
    Carr BI; Akkiz H; Bag HG; Karaoğullarından U; Yalçın K; Ekin N; Özakyol A; Altıntaş E; Balaban HY; Şimşek H; Uyanıkoğlu A; Balkan A; Kuran S; Üsküdar O; Ülger Y; Güney B; Delik A
    J Transl Sci; 2021 Jun; 7(3):. PubMed ID: 34540270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-reactive protein and hepatocellular carcinoma: analysis of its relationships to tumor factors.
    Carr BI; Akkiz H; Guerra V; Üsküdar O; Kuran S; Karaoğullarından Ü; Tokmak S; Ballı T; Ülkü A; Akçam T; Delik A; Arslan B; Doran F; Yalçın K; Altntaş E; Özakyol A; Yücesoy M; Bahçeci Hİ; Polat KY; Ekinci N; Şimşek H; Örmeci N; Sonsuz A; Demir M; Kılıç M; Uygun A; Demir A; Yilmaz S; Tokat Y
    Clin Pract (Lond); 2018; 15(Spec Issue):625-634. PubMed ID: 29951199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macroscopic Portal Vein Thrombosis in HCC Patients.
    Akkiz H; Carr BI; Kuran S; Karaoğullarından Ü; Üsküdar O; Tokmak S; Arslan B; Doran F; Balli HT; Ülkü A; Akçam TA; Bahçeci Hİ; Polat KY; Örmeci N; Şimşek H; Sonsuz A; Demir A; Altıntaş E; Demir M; Yalçın K; Ekinci N; Harmancı Özakyol A; Yücesoy M; Uygun A; Guerra V; Delik A; Tokat Y; Yilmaz S; Bektaş A; Kılıç M
    Can J Gastroenterol Hepatol; 2018; 2018():3120185. PubMed ID: 30009156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The C-reactive protein/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma.
    Kinoshita A; Onoda H; Imai N; Iwaku A; Oishi M; Tanaka K; Fushiya N; Koike K; Nishino H; Matsushima M
    Ann Surg Oncol; 2015 Mar; 22(3):803-10. PubMed ID: 25190127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of Hepatocellular Carcinoma Aggressiveness Factors in Turkish Patients.
    Akkiz H; Carr BI; Yalçın K K; Guerra V; Kuran S; Altıntaş E; Üsküdar O; Karaoğullarından Ü; Özakyol A; Tokmak S; Yücesoy M; Bahçeci Hİ; Ülkü A; Akçam T; Yalçın Polat K; Ekinci N; Şimşek H; Örmeci N; Sonsuz A; Demir M; Kılıç M; Uygun A; Ballı T; Demir A; Arslan B; Doran F
    Oncology; 2018; 94(2):116-124. PubMed ID: 29207378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-Reactive Protein and Platelet-Lymphocyte Ratio as Potential Tumor Markers in Low-Alpha-Fetoprotein Hepatocellular Carcinoma.
    Suner A; Carr BI; Akkiz H; Karakülah G; Üsküdar O; Yalçın K; Kuran S; Tokat Y; Yilmaz S; Özakyol A; Tokmak S; Ballı T; Yücesoy M; Bahçeci Hİ; Ülkü A; Akçam T; Polat KY; Ekinci N; Şimşek H; Örmeci N; Sonsuz A; Demir M; Kılıç M; Uygun A; Demir A; Delik A; Arslan B; Doran F; Altıntaş E; Temel T; Bektaş A
    Oncology; 2019; 96(1):25-32. PubMed ID: 30336489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma.
    Hashimoto K; Ikeda Y; Korenaga D; Tanoue K; Hamatake M; Kawasaki K; Yamaoka T; Iwatani Y; Akazawa K; Takenaka K
    Cancer; 2005 May; 103(9):1856-64. PubMed ID: 15779015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma.
    Oh BS; Jang JW; Kwon JH; You CR; Chung KW; Kay CS; Jung HS; Lee S
    BMC Cancer; 2013 Feb; 13():78. PubMed ID: 23409924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microscopic Portal Vein Invasion in Relation to Tumor Focality and Dimension in Patients with Hepatocellular Carcinoma.
    Carr BI; Guerra V; Donghia R; Ince V; Akbulut S; Ersan V; Usta S; Isik B; Samdanci E; Yilmaz S
    J Gastrointest Surg; 2022 Feb; 26(2):333-340. PubMed ID: 34506030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Albumin in Growth Inhibition in Hepatocellular Carcinoma.
    Bağırsakçı E; Şahin E; Atabey N; Erdal E; Guerra V; Carr BI
    Oncology; 2017; 93(2):136-142. PubMed ID: 28486226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of serum C-reactive protein level on the prognosis of patients with hepatocellular carcinoma undergoing TACE.
    Jun CH; Ki HS; Lee KH; Park KJ; Park SY; Cho SB; Park CH; Joo YE; Kim HS; Choi SK; Rew JS
    Clin Mol Hepatol; 2013 Mar; 19(1):70-7. PubMed ID: 23593612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low Alpha-Fetoprotein Levels Are Associated with Improved Survival in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis.
    Carr BI; Guerra V
    Dig Dis Sci; 2016 Mar; 61(3):937-47. PubMed ID: 26576554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.